Friday, 27 Mar 2020

You are here

Adherence to ETN/MTX is Greater Than Triple DMARD Therapy

Rheumatoid management hinges on choosing your best therapies first. Landmark studies, such as the TEAR,  SWEFOT, and RACAT trials have questioned the comparative efficacy of initial triple DMARD therapy (methotrexate, sulfasalazine,hydroxychloroquine) and combination therapy with methotrexate (MTX) plus etanercept (ETN). While the efficacy statistics suggest initial triple DMARD therapy is more cost effective and equally beneficial to the biologic comparator, these data have not assessed adherence to such therapies as an outcome measure.

Bonafede and coworkers have analyzed commercial claims data and compared 3,724 RA patients who were treated with the combinatoin of ETN-MTX and compared them to 818 triple-DMARD therapy patients. Adherence was assessed as >80% coverage for a particular regimen and persistence was defined as no >45 day gap in treatment and no addition or switch to other DMARDs. At 1 year, 27.9% on ETN-MTX and 18.2% on triple-DMARD therapy were adherent (P < 0.0001) and 29.4% on ETN-MTX and 23.2% on triple DMARD therapy were persistent (P < 0.001). The adjusted odds ratio of being adherent favored the combination of ETN-MTX (OR 1.79; 95% CI 1.47, 2.17) compared with patients on triple-DMARD therapy.

Disclosures: 
The author has received research/grant financial support on this subject
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Start with Anti-TNF in RA? Not So Fast

The suggestion to hit rheumatoid arthritis (RA) early and hard with biologic therapies itself took a hit in a new study.

Use of first-line etanercept (Enbrel) plus methotrexate in very early RA was not associated with a substantially higher rate of remission compared with a strategy of treat-to-target methotrexate monotherapy, a randomized open-label trial found.

Best of 2019 - The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.